New York, NY–(BUSINESS WIRE)–Novavax, Inc., a biopharmaceutical company developing a novel antiviral drug that is approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of acute and chronic obstructive pulmonary disease (COPD), announced today that the company has identified over 500 new cases of coronaviruses worldwide and has more than 2,400 additional patients with additional confirmed cases in the United States.
In addition, the company said it has identified more than 7,300 additional patients globally with new coronaviral cases.
The new news comes a week after the FDA announced a partial suspension of the company’s two-drug regimen, called ARVA-2, in the U, which could have led to additional deaths.
Novavax said in a statement that the suspension was needed to ensure the safety of its drug regimen.
The FDA announced late Wednesday that it was halting the two-week suspension of ARVA2 for a variety of reasons.
In a statement, FDA Commissioner Dr. Stephen Breyer said the agency had determined that the new data “do not suggest a change in the optimal dosing regimen or the drug’s therapeutic benefit” for ARVA 2.
Novavox said in its statement that it would continue to provide continued information to the public on the status of its ongoing clinical trials, including to patients and their healthcare providers.
Novovax’s ARVA program has been approved by U.K. regulators and is being tested in the country.
The company said the company is working closely with U.k. authorities and the U